Business
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Hig...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n\n\n\n\n\n\n\nExpanded clinical studies to amass clinical proof that pelareorep significantly boosts the effectiveness of high-profile checkpoint inhibitors in breast cancer, multiple myeloma and other cancers\nReported a clinical biomarker to identify cancer patients most likely to respond to pelareorep\nDemonstrated clinically that pelareorep reverses the immunosuppressive microenvironments of tumors\nManagement hosting a conference call and webcast today at 4:30 pm ET\nCanada NewsWire\nSAN DIEGO and CALGARY, Alberta, Aug. 4, 2020\n\n\n\nSAN DIEGO and CALGARY, Alberta, Aug. 4, 2020 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.\n\"I'm thrilled with the progress made by Oncolytics last quarter, as we achieved numerous value-creating clinical milestones despite the unpredictable challenges presented by COVID-19,\" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech Inc. \"Importantly, we collected critical mechanistic, biomarker, and proof of concept data that advanced our lead breast cancer program.  We initiated dosing in our phase 2 BRACELET-1 trial and are enrolling patients in our AWARE-1 study following an expansion in the number of study sites. I am particularly pleased with recent AWARE-1 data presented at the European Society for Medical Oncology (ESMO) Breast Cancer Meeting, which confirm pelareorep's mechanism of action and highlight its potential to synergistically combine with checkpoint inhibitors and increase t...